US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

REX CRYPTO EQUITY PREMIUM INCOME ETF

39.90

+0.09000.23%

Post-market: 40.000.0958+0.24%18:45 EDT

Volume:26.33K

Turnover:1.05M

Market Cap:- -

PE:- -

High:40.01

Open:39.96

Low:39.62

Close:39.81

Loading ...

Overview Company News Filings

DYAI: CEPI Grants Recognize C1

Zacks Small Cap Research

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Dyadic International receives a funding award from CEPI

Press Release: Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

Press Release: Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®

Indonesia Seeks CEPI's Support for Tuberculosis Vaccine Development

Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CEPI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CEPI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEPI\",,,,,undefined,":{"symbol":"CEPI","market":"US","secType":"STK","nameCN":"REX CRYPTO EQUITY PREMIUM INCOME ETF","latestPrice":39.9,"timestamp":1751054400000,"preClose":39.81,"halted":0,"volume":26326,"hourTrading":{"tag":"盘后","latestPrice":39.9958,"preClose":39.9,"latestTime":"18:45 EDT","volume":14,"amount":558.9,"timestamp":1751064322765},"delay":0,"floatShares":1140000,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.09,"latestTime":"06-27 16:00:00 EDT","open":39.96,"high":40.01,"low":39.6201,"amount":1049532.85028,"amplitude":0.009794,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":39.81,"sharesOutstanding":1140000,"nav":39.72,"aum":45280800,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":39.9,"preClose":39.83,"latestTime":"09:10 EDT","volume":111,"amount":4448.855247,"timestamp":1751029831671},"postHourTrading":{"tag":"盘后","latestPrice":39.9958,"preClose":39.9,"latestTime":"18:45 EDT","volume":14,"amount":558.9,"timestamp":1751064322765},"volumeRatio":0.6698352750332851,"impliedVol":0.2468,"impliedVolPercentile":0.3306},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEPI\",,,,,undefined,":{"symbol":"CEPI","floatShares":1140000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6698352750332851,"shares":0,"dividePrice":0,"high":40.01,"amplitude":0.009794,"preClose":39.81,"low":39.6201,"week52Low":31.35,"pbRate":"--","week52High":52.16,"institutionHeld":0,"latestPrice":39.9,"eps":0,"divideRate":0,"volume":26326,"delay":0,"ttmEps":0,"open":39.96,"prevYearClose":46.52,"prevWeekClose":39.52,"prevMonthClose":37.43,"prevQuarterClose":36.88,"fiveDayClose":39.52,"twentyDayClose":37.78,"sixtyDayClose":37.83},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CEPI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522783532","title":"DYAI: CEPI Grants Recognize C1","url":"https://stock-news.laohu8.com/highlight/detail?id=2522783532","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522783532?lang=en_us&edition=fundamental","pubTime":"2025-03-27 23:23","pubTimestamp":1743088980,"startTime":"0","endTime":"0","summary":"Dyadic International Inc.  announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next months. We are most excited about the partnership with Proliant Health. Dyadic signed a deal in June with Proliant which has so far generated multiple milestone payments while preparing for commercialization of animal-free recombinant albumin products manufactured using C1. We anticipate albumin product sales in 2Q:25. Later this year, product sales from non-animal dairy enzymes with partner Inzymes are forecast to flow through the door. Several grant awards have also been announced, including a Gates Foundation award and two Coalition for Epidemic Preparedness Innovation  awards, which are also backed by the Gates Foundation.Dyadic released 2024 operational and financial results in a press release on March 26th, 2025, filed its Form 10-K with the SEC and held a conference call with investors. Since the last quarterly update, Dyadic partici","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dyai-cepi-grants-recognize-c1-152300804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DYAI","BK4139","CEPI"],"gpt_icon":0},{"id":"2521765797","title":"Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion","url":"https://stock-news.laohu8.com/highlight/detail?id=2521765797","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521765797?lang=en_us&edition=fundamental","pubTime":"2025-03-24 14:00","pubTimestamp":1742796000,"startTime":"0","endTime":"0","summary":"Saint Herblain , March 24, 2025 – Valneva SE , a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine IXCHIQ. In agreement and with support from the local public health agency, the Agence Régionale de Santé La Réunion, Valneva will provide 40,000 doses starting early April, with an option to provide more, through distribution agreements with the Island’s wholesalers. This supply of doses, paid for by the French authorities, is in line with the recommendation of France’s national public health agency, the Haute Autorité de Santé , to prioritize for vaccination adults aged 65 and over, with co-morbidities. IXCHIQ remains available for purchase in France .Valneva is focused on expanding the vaccine’s label and access. In the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness 8, with support from the EU Horizon Europe p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-responds-french-government-call-060000542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SII","VALN","CDC","BK4566","CEPI","INRLF","BK4588","HAS","BK4190","BK4135","BK4139","BK4585"],"gpt_icon":0},{"id":"2520456407","title":"Dyadic International receives a funding award from CEPI","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456407?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:40","pubTimestamp":1742474420,"startTime":"0","endTime":"0","summary":"Dyadic International (DYAI) announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vacci...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dyadic-international-receives-a-funding-award-from-cepi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dyadic-international-receives-a-funding-award-from-cepi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CEPI","DYAI","BK4139"],"gpt_icon":0},{"id":"2520456869","title":"Press Release: Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2520456869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520456869?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:30","pubTimestamp":1742473800,"startTime":"0","endTime":"0","summary":"JUPITER, Fla., March 20, 2025  -- Dyadic International, Inc.  , a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines.CEPI is providing US$4.5 million to non-profit Fondazione Biotecnopolo di Siena  for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus--applying technology owned by Dyadic--is a faster and cost-effective alternative to the more established route of producing antigens in mammalian cells.Dr Raafat Fahim, Interim Executive Director of Manufacturing and Supply Chain, CEPI, said, \"Protein-based vaccines play a crucial role in combating emerging infectious diseases. However, the current manufacturing processes for producing these vacc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CEPI","03160","TM","BK4555","DYAI","BK4588","BK4099","AAQC","BK4604","BK4139"],"gpt_icon":0},{"id":"2520172076","title":"Press Release: Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2520172076","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520172076?lang=en_us&edition=fundamental","pubTime":"2025-03-20 14:00","pubTimestamp":1742450400,"startTime":"0","endTime":"0","summary":"-- Met 2024 growth targets for product sales  and total. -- Strong year-end cash position of EUR168.3 million including sale of. Priority Review Voucher1, successful private placement and 67% reduction. -- Substantial clinical and regulatory progress in 2024; further data. readouts, product approvals and label extensions anticipated in 2025. -- 2025 outlook reflects solid revenue growth and positive commercial cash. flows to support strategic R&D investments with lower operating cash burn. Saint-Herblain , March 20, 2025 -- Valneva SE , a specialty vaccine company, today reported its consolidated financial results for the year ended December 31, 2024 and provided key corporate updates and guidance for its future results. The consolidated financial results are available on the Company's website .-- Product sales reached EUR163.3 million for the year ended December 31,2024 compared to EUR144.6 million in the same period of 2023, an increase. compared to EUR153.7 million for the year ende","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4087","BK4139","CHMP","CEPI","SII","BK4135","BK4022","CHIM","VALN","BK4232","R"],"gpt_icon":0},{"id":"2516712473","title":"Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®","url":"https://stock-news.laohu8.com/highlight/detail?id=2516712473","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516712473?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:45","pubTimestamp":1740761100,"startTime":"0","endTime":"0","summary":"If granted, IXCHIQ will become the first vaccine against the chikungunya virus  available in the EU for adolescents 12 years of age and older. Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative to ensure the vaccine is available to all age groups. Therefore, this positive CHMP opinion marks a crucial milestone toward introducing a more robust preventative solution against chikungunya in the EU. Broader accessibility will help provide protection and mitigate the burden of this debilitating illness, which is continuing to spread in areas that were previously unaffected.”The CHMP positive opinion follows four regulatory approvals in the U.S6., Europe7, Canada8 and the UK9 in adults 18 years of age and older. Valneva expects to receive marketing approval in Brazil in the first quarter of 2025, which would represent the first approval in an ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-receives-ema-positive-chmp-164500042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4539","SII","CEPI","INRLF","BK4156","EC","VALN","BK4135","BK4201","CHMP","BK4087"],"gpt_icon":0},{"id":"2511640115","title":"Indonesia Seeks CEPI's Support for Tuberculosis Vaccine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2511640115","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511640115?lang=en_us&edition=fundamental","pubTime":"2025-02-15 10:14","pubTimestamp":1739585640,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - Deputy Foreign Minister Arrmanatha Christiawan Nasir reaffirmed Indonesia’s commitment to strengthening the global health architecture in anticipation of future pandemics. This sta","market":"us","thumbnail":"https://statik.tempo.co/data/2025/02/13/id_1377090/1377090_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/02/13/id_1377090/1377090_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1975688/indonesia-seeks-cepis-support-for-tuberculosis-vaccine-development","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["CEPI"],"gpt_icon":0},{"id":"2505278755","title":"Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2505278755","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505278755?lang=en_us&edition=fundamental","pubTime":"2025-01-21 20:05","pubTimestamp":1737461100,"startTime":"0","endTime":"0","summary":"Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents  for its single-shot chikungunya virus  vaccine, IXCHIQ. For investors’ note, IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need.The trial data supports and strengthens the pivotal data previously reported for adolescents in the United States, Europe and Canada. Data from this trial are also expected to support the licensure of IXCHIQ in Brazil.The new favorable data from the Phase 3 trial helped Valneva advance the furthest along the clinical development timeline.Subsequent to the news, the share price of VALN jumped 1.4% to $4.37 yesterday.The latest development is capable of generating positive market sentiment, considering the rising number of chikungunya cases in select geographies. We therefore expect market sentiment toward VALN stock to be positive surrounding this news.Additionally, the compan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/favorable-vla1553-321-phase-3-120500966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4539","BK4139","BK4585","BK4082","INRLF","BK4548","BK4156","BK4167","BK4588","BK4504","VCYT","RMD","BK7501","CEPI","LU2008162690.USD","RMD.AU","BK4567","VALN","OMCL","LU2177674079.SGD","BK7007"],"gpt_icon":0},{"id":"2505238242","title":"Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2505238242","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505238242?lang=en_us&edition=fundamental","pubTime":"2025-01-21 00:45","pubTimestamp":1737391500,"startTime":"0","endTime":"0","summary":"Geometric mean antibody titers  consistently surpassed the seroresponse threshold defined with the U.S. Food and Drug Administration 7 as the surrogate of protection in baseline seronegative participants who received a single dose of the vaccine.Conducted in collaboration with Instituto Butantan in Brazil and funded by the Coalition for Epidemic Preparedness Innovations  with support from the European Union ’s Horizon 2020 program, the VLA1553-321 trial represents the first clinical trial conducted in an endemic area and with individuals previously infected with CHIKV. This trial supported the submission of label extension applications to the U.S. Food and Drug Administration 8, the European Medicines Agency  and Health Canada9 to po","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/valneva-reports-high-sustained-immune-164500324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SII","VALN","BK4135","CEPI","BK4156","BK4139","INRLF"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CEPI\",params:#limit:5,,,undefined,":[{"date":"2025-06-24","symbol":"CEPI","amount":1.3797,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-06-25"},{"date":"2025-05-29","symbol":"CEPI","amount":1.3881,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-29","defaultRemindTime":1748525400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-29","currency":"USD","dateTimestamp":1748491200000,"payDate":"2025-05-30"},{"date":"2025-04-29","symbol":"CEPI","amount":1.3286,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-30","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-04-30"},{"date":"2025-03-25","symbol":"CEPI","amount":1.45915,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-03-26"},{"date":"2025-02-25","symbol":"CEPI","amount":1.57775,"announcedDate":"2025-02-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-25","defaultRemindTime":1740493800000,"name":"REX CRYPTO EQUITY PREMIUM INCOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-26","payableDate":"2025-02-25","currency":"USD","dateTimestamp":1740459600000,"payDate":"2025-02-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CEPI\",market:\"US\",,,undefined,":[{"executeDate":"2025-01-28","recordDate":"2025-01-28","paymentDate":"2025-01-29","value":1.69835,"currency":"USD"},{"executeDate":"2025-02-25","recordDate":"2025-02-25","paymentDate":"2025-02-26","value":1.57775,"currency":"USD"},{"executeDate":"2025-03-25","recordDate":"2025-03-25","paymentDate":"2025-03-26","value":1.45915,"currency":"USD"},{"executeDate":"2025-04-29","recordDate":"2025-04-29","paymentDate":"2025-04-30","value":1.3286,"currency":"USD"},{"executeDate":"2025-05-29","recordDate":"2025-05-29","paymentDate":"2025-05-30","value":1.3881,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CEPI\",market:\"US\",delay:false,,,undefined,":{}}}